TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16623031

Group type: EXPERIMENTAL
Intervention: Computer-assisted instruction (CAI) on Ascaris lumbricoides
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hard copy lessons on Ascaris lumbricoides
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Computer-assisted instruction (CAI) on Enterobius vermicularis
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hard copy lessons on Enterobius vermicularis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Computer-assisted instruction (CAI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hard copy lessons
Number of subjects: 60
Study: 12037148

Group type: EXPERIMENTAL
Intervention: hOKT3gamma1(Ala‐Ala) monoclonal antibody treatment for 14 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no antibody treatment)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: hOKT3gamma1(Ala‐Ala) monoclonal antibody treatment
Number of subjects: 24
Study: 10216324

Group type: EXPERIMENTAL
Intervention: Benzyl alcohol 9% with 1:100,000 epinephrine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lidocaine 1% with 1:100,000 epinephrine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (physiologic saline solution)
Number of subjects: 30
Study: 8251017

Group type: EXPERIMENTAL
Intervention: Peer-pressure resistance skills program
Number of subjects: 168

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 168
Study: 3505528

Group type: EXPERIMENTAL
Intervention: Wheezers Anonymous (WA) program
Number of subjects: 79

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 79
Study: 29861803

Group type: EXPERIMENTAL
Intervention: PECS II block
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 26857829

Group type: EXPERIMENTAL
Intervention: Multicomponent sun protection program (read-along book, swim shirt, weekly text-message reminders)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (information usually provided at a well-child visit)
Number of subjects: 300
Study: 24534682

Group type: EXPERIMENTAL
Intervention: Multi-media tablet device delivering graphic and verbal information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Audio device delivering verbal information only
Number of subjects: 0
Study: 22466971

Group type: EXPERIMENTAL
Intervention: Endovascular hypothermia
Number of subjects: 26
Study: 20578922

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (SALC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anesthesia (GALC)
Number of subjects: 60
Study: 18051666

Group type: EXPERIMENTAL
Intervention: Jail reentry programs tailored to gender, age, and ethnic/racial differences
Number of subjects: 1946
Study: 16083521

Group type: EXPERIMENTAL
Intervention: Trazodone prolonged release 150-450 mg/day (n = 55)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Paroxetine 20-40 mg/day (n = 53)
Number of subjects: 108
Study: 12404164

Group type: EXPERIMENTAL
Intervention: Repeated treatment with praziquantel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (children who did not receive chemotherapy)
Number of subjects: 0
Study: 10594405

Group type: EXPERIMENTAL
Intervention: L-NMMA
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: L-Arginine (L-Arg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: L-NMMA + L-Arg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 18
Study: 8677930

Group type: EXPERIMENTAL
Intervention: 125-mg 13C urea breath test at 30 min
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 250-mg 13C urea breath test at 40 min
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 125-mg 13C urea breath test
Number of subjects: 120
Study: 1961376

Group type: EXPERIMENTAL
Intervention: Azathioprine (Germed) 50 or 75 mg daily depending on body weight, treatment stopped after two months for one month
Number of subjects: 21

Group type: COMPARATOR
Intervention: Prednisone (Encorton, Polfa) 5 or 10 mg daily
Number of subjects: 21
Study: 30704795

Group type: EXPERIMENTAL
Intervention: Prostatectomy
Number of subjects: 3953

Group type: COMPARATOR
Intervention: Radiation therapy
Number of subjects: 3953
Study: 26971745

Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shockwave therapy (rESWT) - 0.340 mJ/mm2, 2000 shots
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shockwave therapy (rESWT)
Number of subjects: 12
Study: 25895021

Group type: EXPERIMENTAL
Intervention: IPX066 (carbidopa-levodopa)
Number of subjects: 617
Study: 22913655

Group type: EXPERIMENTAL
Intervention: Short Form of the Mini-Mental State Examination (SMMSE)
Number of subjects: 606
Study: 22090070

Group type: EXPERIMENTAL
Intervention: Expiratory flow increase technique (EFIT) performed 2 hours after feeding
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Expiratory flow increase technique (EFIT) performed 3 hours after feeding
Number of subjects: 18
Study: 19089890

Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg twice per day + Vaginal conjugated equine estrogen 0.625 mg twice a week
Number of subjects: 80

Group type: COMPARATOR
Intervention: Tolterodine 2 mg twice per day
Number of subjects: 80
Study: 16860807

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 14969666

Group type: EXPERIMENTAL
Intervention: NuvaRing with tampons
Number of subjects: 14

Group type: COMPARATOR
Intervention: NuvaRing alone
Number of subjects: 14
Study: 11430419

Group type: EXPERIMENTAL
Intervention: Standard-dose lenograstim (263 microg/day)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Low-dose lenograstim (131.5 microg/day)
Number of subjects: 44
Study: 9551010

Group type: EXPERIMENTAL
Intervention: Family planning intervention with husband's participation
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Usual family planning care
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Family planning intervention targeting wife only
Number of subjects: 1800
Study: 9315987

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 671

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 671
Study: 2635871

Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg suppositories twice daily)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo (placebo suppositories)
Number of subjects: 112
Study: 415870

Group type: EXPERIMENTAL
Intervention: 4-methylpyrazole (4-MP, 7 mg/kg body wt i.v.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ethanol (0.6 g/kg body wt)
Number of subjects: 0
Study: 31237045

Group type: EXPERIMENTAL
Intervention: Overground gait training with rhythmic auditory stimulation (RAS, n=6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Overground gait training without rhythmic auditory stimulation (GT, n=6)
Number of subjects: 12
Study: 30552951

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 76
Study: 27431576

Group type: EXPERIMENTAL
Intervention: OK-432 plus closed suction drainage
Number of subjects: 80

Group type: COMPARATOR
Intervention: Drainage-only
Number of subjects: 80
Study: 26164096

Group type: EXPERIMENTAL
Intervention: Treatment including doxorubicin (vincristine 1.5 mg/m² + actinomycin D 45 μg/kg + doxorubicin 50 mg/m² every 6 weeks)
Number of subjects: 583

Group type: COMPARATOR
Intervention: Treatment excluding doxorubicin (vincristine 1.5 mg/m² + actinomycin D 45 μg/kg)
Number of subjects: 583
Study: 24166522

Group type: EXPERIMENTAL
Intervention: G‐CSF 1‐6 cycles
Number of subjects: 167

Group type: COMPARATOR
Intervention: G‐CSF 1‐2 cycles
Number of subjects: 167

Group type: COMPARATOR
Intervention: G‐CSF 1‐6 cycles vs G‐CSF 1‐2 cycles
Number of subjects: 167
Study: 21305315

Group type: EXPERIMENTAL
Intervention: Primary vitrectomy (PV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scleral buckling (SB)
Number of subjects: 0
Study: 19476724

Group type: EXPERIMENTAL
Intervention: GlucoWatch Biographer
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: MiniMed Continuous Glucose Monitoring System (CGMS)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Attention control group (standard treatment with nurse feedback)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 404
Study: 17708161

Group type: EXPERIMENTAL
Intervention: HyperHaes solution (250ml 7.2% NaCl/6% HES solution)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ringer's acetate (500 ml Ringer's acetate solution)
Number of subjects: 80
Study: 14767730

Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 10
Study: 11521723

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus trastuzumab (Herceptin)
Number of subjects: 469

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 469
Study: 9475695

Group type: EXPERIMENTAL
Intervention: Pyrethrin-piperonyl-butoxide pediculicide (RID; Py-PB)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Permethrin pediculicide (NIX; PM)
Number of subjects: 190
Study: 7846590

Group type: EXPERIMENTAL
Intervention: Direct current stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No direct current stimulation (Control)
Number of subjects: 0
Study: 3285731

Group type: EXPERIMENTAL
Intervention: Clonidine po approximately 5 micrograms.kg‐1
Number of subjects: 80

Group type: COMPARATOR
Intervention: Diazepam po (0.1 mg.kg‐1)
Number of subjects: 80
Study: 29294791

Group type: EXPERIMENTAL
Intervention: Empowering Youth Through Interpersonal Violence Prevention Program (EYIPP)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: EYIPP
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (those who refused to participate in services)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (eligible youths who declined services)
Number of subjects: 24
Study: 30942015

Group type: EXPERIMENTAL
Intervention: Warm moxibustion combined with conventional quadriceps strength training
Number of subjects: 174

Group type: COMPARATOR
Intervention: Conventional quadriceps strength training
Number of subjects: 174
Study: 28551531

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pharmacological methods (Control group)
Number of subjects: 50
Study: 25111236

Group type: EXPERIMENTAL
Intervention: Combination of an angiotensin I-converting enzyme inhibitor and angiotensin II-receptor blocker
Number of subjects: 558

Group type: COMPARATOR
Intervention: Angiotensin I-converting enzyme inhibitor alone
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Low blood pressure (<110/75 mm Hg)
Number of subjects: 558

Group type: COMPARATOR
Intervention: Standard blood pressure (120-130/70-80 mm Hg)
Number of subjects: 558
Study: 24112359

Group type: EXPERIMENTAL
Intervention: Newborn chlorhexidine cleansing
Number of subjects: 18985

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding
Number of subjects: 18985

Group type: EXPERIMENTAL
Intervention: No exclusive breastfeeding
Number of subjects: 18985
Study: 21954530

Group type: EXPERIMENTAL
Intervention: T-piece (4 L/min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: CPAP (PEEP <= 5 cm H2O, FiO2 <= 0.4)
Number of subjects: 40
Study: 19700946

Group type: EXPERIMENTAL
Intervention: Brief psychosocial therapy (BPST) for 4 weeks
Number of subjects: 318
Study: 16917884

Group type: EXPERIMENTAL
Intervention: Kid's Block Food Frequency Questionnaire (Kid's Block FFQ)
Number of subjects: 61

Group type: COMPARATOR
Intervention: 24-hour recall
Number of subjects: 61
Study: 15324466

Group type: EXPERIMENTAL
Intervention: Levamisole (2.5 mg/kg) alone
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Levamisole (2.5 mg/kg) plus Ivermectin (200 microg/kg)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Levamisole (2.5 mg/kg) plus Albendazole (400 mg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Ivermectin (200 microg/kg) alone
Number of subjects: 66

Group type: COMPARATOR
Intervention: Albendazole (400 mg) alone
Number of subjects: 66
Study: 11153551

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (2 microg/kg) 5 min before MH placement
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Local lidocaine infiltration (3 ml 1% plain lidocaine) at each pin site 1 min before MH placement
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl + local lidocaine infiltration
Number of subjects: 45
Study: 9342546

Group type: EXPERIMENTAL
Intervention: 37/40 kD antibodies in Type 1a diabetic patients
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: 37/40 kD antibodies in Type 1b diabetic patients
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: GAD antibodies and/or 37/40 kD antibodies
Number of subjects: 225

Group type: COMPARATOR
Intervention: GAD antibodies in schoolchildren
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Combination of ICA with at least two other markers in relatives
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Development of diabetes in ICA-positive non-diabetic subjects
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Combination of multiple antibodies in ICA-positive non-diabetic subjects
Number of subjects: 225

Group type: COMPARATOR
Intervention: Association of ICA with at least two other markers in non-progressing subjects
Number of subjects: 225
Study: 1547194

Group type: EXPERIMENTAL
Intervention: niacin/colestipol plus diet therapy
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: computer-based quantitative coronary angiography (QCA)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: panel-based estimates
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: QCA
Number of subjects: 350
Study: 3939740

Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 30712391

Group type: EXPERIMENTAL
Intervention: Esmirtazapine (2.25, 4.5, 9.0, or 18.0 mg)
Number of subjects: 1888

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1888
Study: 30112861

Group type: EXPERIMENTAL
Intervention: Chronic outdoor urban pollution (Baoding)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Moderate outdoor urban pollution (Dalian)
Number of subjects: 204
Study: 26481674

Group type: EXPERIMENTAL
Intervention: Real-time fMRI neurofeedback (rtfMRI NF)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham feedback (Control group)
Number of subjects: 16
Study: 25339753

Group type: EXPERIMENTAL
Intervention: Anodal tsDCS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cathodal tsDCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tsDCS
Number of subjects: 0
Study: 22607563

Group type: EXPERIMENTAL
Intervention: Intermittent granulocyte and monocyte apheresis (GMA)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Oral mercaptopurine (0.5 mg/kg per day)
Number of subjects: 21
Study: 21135366

Group type: EXPERIMENTAL
Intervention: ICD (n=311)
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: ICD with appropriate therapy
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: ICD with no appropriate therapy
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: ICD shock therapy
Number of subjects: 653

Group type: COMPARATOR
Intervention: Standard medical therapy (Control, n=342)
Number of subjects: 653
Study: 17624213

Group type: EXPERIMENTAL
Intervention: Ginseng supplementation (3 grams of 100% ginseng orally daily for 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (lactose powder, same dosage and duration as ginseng)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ginseng supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15903359

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (6 g of creatine monohydrate per day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12167507

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 9523367

Group type: EXPERIMENTAL
Intervention: Fenoterol inhalation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 14
Study: 9638196

Group type: EXPERIMENTAL
Intervention: Late potentials (LP) group (25 patients)
Number of subjects: 125

Group type: COMPARATOR
Intervention: No late potentials (LP) group (100 patients)
Number of subjects: 125
Study: 2782125

Group type: EXPERIMENTAL
Intervention: Craving as a strong desire
Number of subjects: 0

Group type: COMPARATOR
Intervention: Craving as any desire or urge
Number of subjects: 0
Study: 336651

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benztropine
Number of subjects: 0
Study: 31641729

Group type: EXPERIMENTAL
Intervention: Low RBC DHA-EPA concentration (≤4.82%)
Number of subjects: 1680

Group type: EXPERIMENTAL
Intervention: Increase in RBC DHA-EPA from baseline
Number of subjects: 1680
Study: 29039802

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 22)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (n = 23)
Number of subjects: 45
Study: 26042474

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 37
Study: 23676577

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg once daily
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study: 20512069

Group type: COMPARATOR
Intervention: Male experimenter
Number of subjects: 100

Group type: COMPARATOR
Intervention: Female experimenter
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Participant gender (male)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Participant gender (female)
Number of subjects: 100
Study: 19502534

Group type: EXPERIMENTAL
Intervention: Face-to-face
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Combined Internet and face-to-face
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Internet-only
Number of subjects: 192
Study: 16492101

Group type: EXPERIMENTAL
Intervention: Interpretive bias training favoring threatening meanings
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Interpretive bias training favoring nonthreatening meanings
Number of subjects: 48
Study: 15648983

Group type: EXPERIMENTAL
Intervention: OPEN
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: RESERVOIR
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 20
Study: 11050693

Group type: EXPERIMENTAL
Intervention: EPI-10 (glyceryl trinitrate transdermal patch)
Number of subjects: 24

Group type: COMPARATOR
Intervention: ND-10 (reference patch)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: EPI-10
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: EPI-10 and ND-10
Number of subjects: 24
Study: 9282973

Group type: EXPERIMENTAL
Intervention: 14C-mannitol
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 51Cr-EDTA
Number of subjects: 135

Group type: COMPARATOR
Intervention: Mannitol and 14C-mannitol
Number of subjects: 135

Group type: COMPARATOR
Intervention: Lactulose and 51Cr-EDTA
Number of subjects: 135

Group type: COMPARATOR
Intervention: Age effect on marker excretion
Number of subjects: 135

Group type: COMPARATOR
Intervention: Smoking
Number of subjects: 135
Study: 8192291

Group type: EXPERIMENTAL
Intervention: Significant study results
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Controlled trials
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Randomized trials
Number of subjects: 997
Study: 3576660

Group type: EXPERIMENTAL
Intervention: Chewable tablet formulation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Carbamazepine tablets
Number of subjects: 10
Study: 30194275

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baricitinib 2 mg
Number of subjects: 0
Study: 31158073

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic radical prostatectomy (RALP)
Number of subjects: 4003

Group type: COMPARATOR
Intervention: Open retropubic radical prostatectomy (RRP)
Number of subjects: 4003
Study: 27006510

Group type: EXPERIMENTAL
Intervention: Intensive glucose control (INT)
Number of subjects: 858

Group type: COMPARATOR
Intervention: Standard glycemic treatment (Control)
Number of subjects: 858
Study: 24736279

Group type: EXPERIMENTAL
Intervention: 80 mg of telmisartan
Number of subjects: 20332

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20332

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 20332
Study: 22344551

Group type: EXPERIMENTAL
Intervention: 5 μg exenatide single dose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10 μg exenatide single dose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 5 μg exenatide multiple doses
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10 μg exenatide multiple doses
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Adverse events after 5 μg exenatide
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Adverse events after 10 μg exenatide
Number of subjects: 24
Study: 20843977

Group type: EXPERIMENTAL
Intervention: Thrombolysed patients (n=1585)
Number of subjects: 5817

Group type: COMPARATOR
Intervention: Nonthrombolysed comparators (n=4232)
Number of subjects: 5817
Study: 17681081

Group type: EXPERIMENTAL
Intervention: New dressing containing ceramide 2
Number of subjects: 37

Group type: COMPARATOR
Intervention: No dressing (control)
Number of subjects: 37
Study: 15117739

Group type: EXPERIMENTAL
Intervention: Angiotensin deletion allele
Number of subjects: 103
Study: 10940515

Group type: EXPERIMENTAL
Intervention: Human natural leucocytic interferon (HNLI) applied locally at 2x10(6) U daily in pessaries for 21 days before surgery
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no treatment with HNLI)
Number of subjects: 27
Study: 9263140

Group type: EXPERIMENTAL
Intervention: Low dose methotrexate (MTX) plus prednisone > or = 5 mg/day
Number of subjects: 133

Group type: COMPARATOR
Intervention: Prednisone > or = 5 mg/day without MTX
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Low dose methotrexate (MTX)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Non-MTX treated patients
Number of subjects: 133
Study: 8298553

Group type: EXPERIMENTAL
Intervention: CYA and methylprednisolone
Number of subjects: 25

Group type: COMPARATOR
Intervention: CYA and methotrexate (MTX)
Number of subjects: 25